CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
  • Home
    • About
      • Message from the Editor-in-Chief
      • Mission Statement
      • Editorial Board
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
Search
  • Home
    • About
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
Follow US
AHA 2026News

Coordinated Nonpharmacologic Care Does Not Improve Orthostatic Intolerance in Long COVID POTS: RECOVER-AUTONOMIC 

Nathan Kong MD
Share
5 Min Read

Key Points:

  • Postural orthostatic tachycardia syndrome (POTS) affects approximately 30% of patients with Long COVID. Nonpharmacologic measures are first-line therapy, but the supporting evidence comes largely from small nonrandomized studies.
  • Within the RECOVER-AUTONOMIC platform trial, 381 adults with Long COVID POTS across 50 US sites were randomized to coordinated nonpharmacologic care, including weekly telehealth sessions with a trained care coordinator, or usual care consisting of a one-page instruction sheet.
  • Coordinated care did not improve orthostatic intolerance at 3 months compared with usual care, with consistent results across all secondary end points, although study completion was higher with coordinated care.

Postural orthostatic tachycardia syndrome (POTS) affects approximately 30% of patients with Long COVID and is often chronic and disabling. Nonpharmacologic measures, including use of fluids, salt, compression garments, counter-pressure maneuvers, and recumbent activity, are considered first-line therapies. However, the supporting evidence comes from small nonrandomized studies conducted mostly before the COVID-19 pandemic, and coordinated delivery of these measures has not been tested against a simple instruction sheet in an adequately powered trial.

RECOVER-AUTONOMIC was a National Institutes of Health-funded platform trial conducted at 50 US sites between April 2024 and July 2025. The study enrolled adults with prior SARS-CoV-2 infection, symptoms for at least 12 weeks, and a heart rate rise of at least 30 bpm on active stand or tilt testing without orthostatic hypotension. Participants were enrolled into one of two drug appendices, intravenous immunoglobulin (IVIG) versus placebo (n=200) or ivabradine versus placebo (n=181); they were additionally randomized to open-label coordinated nonpharmacologic care (n=189) or usual care (n=192). The ivabradine comparison was reported separately at ACC.26 in March 2026, where ivabradine did not improve quality of life, and the IVIG results are expected to be presented at a later date. Both groups received the same recommendations and a wearable activity tracker. Coordinated care added a booklet and daily logbook, weekly telehealth sessions with a trained care coordinator for 3 months with individualized feedback and motivational support, a home blood pressure monitor, and an under-desk exercise bicycle with activity guidance, while usual care consisted of a one-page instruction sheet. The primary end point was the change in the OHQ/OIQ composite score of orthostatic intolerance (0 to 10, higher is worse) from baseline to 3 months.

The results were presented at the American Heart Association (AHA) Scientific Sessions on November 9, 2026. The average age was 39 years, over 80% of participants were women, and the mean heart rate rise on active stand was 37 to 39 bpm. At 3 months, coordinated care did not significantly improve the orthostatic intolerance score compared with usual care (adjusted difference 0.25; 95% confidence interval [CI] −0.10 to 0.60, P=0.167). Results were consistent in both the IVIG and ivabradine appendices and across sensitivity analyses. There were also no differences in any secondary end point, including the COMPASS-31 and Malmö POTS symptom scores, active stand heart rate rise, 6-minute walk distance, and PROMIS physical function. Study completion was higher with coordinated care (90.5% vs. 82.8%). Adverse events occurred in 67.7% versus 58.2% and serious adverse events in 5.9% versus 2.1% of participants receiving coordinated versus usual care. These comparisons were descriptive, without formal statistical testing. There were no deaths. It is important to note the trial was not designed to test whether fluids, salt, compression garments, and exercise work, but whether “greater engagement and intensification” of these measures would further improve function and symptoms.

Limitations of the trial include the open-label nonpharmacologic care assignment, although any resulting bias would be expected to favor coordinated care. Uptake of the individual care components was not measured, and adherence beyond the weekly calls relied on patient report. The appendices also differed in entry thresholds and symptom burden. The higher rate of adverse events with coordinated care may reflect closer ascertainment. 

Presenting the results, Dr. Marat Fudim concluded that “in Long COVID POTS, coordinated nonpharmacologic care did not improve orthostatic intolerance at 3 months compared with an instruction sheet at expert centers,” and that “for symptom goals, a simple instruction sheet may suffice.”

TAGGED:AHA 2026ConferenceFeaturedNews
Share This Article
Copy Link Print
CardiologyNowNews.org CardiologyNowNews.org
Copyright - CardiologyNowNews
  • Contact Us
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?